|
Reference | Age | M/F | Hb (g/L) | Platelets (×109/L) | Plasma-pheresis | Hematological diagnosis | Chemotherapy 1st line | Subsequent chemotherapy | Approximate survival from the beginning of the first therapy for hemolysis (if applicable) or presentation |
|
[9] | 70 | M | 72 | 80 | Yes | TTP | Carboplatin/paclitaxel | | 14 days |
[10] | 52 | F | 72 | 62 | No | MAHA | None | | 1 week |
[10] | 28 | M | 75 | 77 | No | MAHA | None | | 1 week |
[10] | 21 | M | 61 | 342 | No | MAHA | None | | 1 week |
[8] | 62 | M | 107 | 86 | No | MAHA | Etoposide 120 mg/m2, leucovorin 300 mg/m2, and 5-FU 500 mg/m2 days 1–3, every 21 days | 5-FU 2000 mg/m2, leucovorin 500 mg/m2, oxaliplatin 130 mg/m2 day 1 every 14 days | 12 months |
[11] | 19 | M | 100 | 98 | No | MAHA with DIC |
5-FU, adriamycin, and mitomycin-C | | 6 days |
[12] | 61 | F |
95 est | NR | No | Cancer-related thrombotic microangiopathy | Infusional 5-FU 250 mg/m2/day | | 35 days |
[13] | 60 | M | 82 | 43 | Yes | TTP | 5-FU, adriamycin, and mitomycin C | | 6 months |
[14] | 59 | F | 61 | 20 | Yes | TTP | None | | 1 month |
[14] | 65 | F | 80 | 86 | No | TTP | Paclitaxel | | 11 months |
[15] | 52 | M | 60 | 24 | Yes | MAHA without DIC | None | | 4 weeks |
[16] | 75 | M | 81 | NR | No | MAHA | None | | 20 days |
[17] | 58 | F | 58 | 14 | No | MAHA | 5-FU, vincristine, methotrexate, and cyclophosphamide | | 10 days |
[18] | 50 | M | 73 | 50 | Yes | Cancer-associated MAHA | Docetaxel, 5-FU, and platinum | | 12 days |
[4] | 71 | M | 44 | 18 | No | TTP | None | | Curative-intent surgery |
[19] | 25 | F | 74 | 100 | No | MAHA | 5-FU 600 mg/m2 weekly + adriamycin 40 mg/m2 day 1, q21 days | Mitomycin-C 10 mg/m2 monthly | 7 months |
[20] | 28 | F | 52 | 111 | Yes | TTP | Cisplatin/5-FU infusion | | Under 2 months |
[7] | 45 | M | 59 | 50 | No | MAHA and thrombocytopenia | Cisplatin 60 mg/m2 day 1, 5-FU 600 mg/m2/day infusion days 1–4, every 21 days | | 7 weeks |
[7] | 32 | F | NR | NR | Yes | MAHA and thrombocytopenia | Cisplatin 20 mg/m2 days 1–5, etoposide 60 mg/m2 days 1–5, every 21 days | 5-FU 298 (=70% of 425) mg/m2 and leucovorin 20 mg/m2 days 1–5, and weekly cetuximab 500 mg IV, all every 21 days | 12 weeks approx.. |
[5] | 71 | F | 56 | 15.6 | No | MAHA | Mitomycin-C 10 mg and neothramycin (also gabexate infusion), 5 doses over 2 months | | 3 months |
[6] | 69 | M | 65 | 64 | Yes | Thrombotic microangiopathy with renal failure | N/A | | Curative intent surgery |
[21] | 60 | M | 98 | 35 | No | DIC | None | | 24 days |
[22] | 83 | F | 40 | 85 | No | MHA | None | | 3 days |
[23] | 47 | F | 49 | 9 | No | MAHA | Cisplatin 80 mg/m2 day 1, 5-FU 1000 mg/m2/day, days 1–5 | FOLFIRI, DCF at 20% dose reduction | 19 months |
[24] | 69 | F | 96 | 104 | No | MAHA | Adriamycin | | 4 weeks |
[25] | 44 | M | 74 | 71 | No | MAHA and DIC | None | | 3 months |
[26] | 57 | M | 58 | 39 | No | DIC | Methotrexate 100 mg/m2 day 1, 5-FU bolus 600 mg/m2 day 1, LV 10 mg/m2 q6h days 2 and 3, weekly | | 10 months |
[27] | 52 | F | 68 | 18 | No | Thrombotic microangiopathy | 5-FU, cisplatin, and hydroxyurea | | 3 months |
[27] | 51 | M | 74 | 74 | No | Thrombotic microangiopathy | Gemcitabine, oxaliplatin, irinotecan, 5-FU, and docetaxel (details not reported) | | 4 months |
[27] | 59 | M | 66 | 39 | Yes | Thrombotic microangiopathy | None | | 44 days |
[28] | 51 | F | 67 | 40 | Yes | TTP | Vincristine 2 mg | Cisplatin 50 mg/m2days 1 + 15, 5-FU 150 mg/m2, and LV 500 mg weekly | 3 months |
[29] | 59 | F | 86 | 23 | No | DIC | None | | 10 days |
[29] | 51 | F | 39 | 120 | No | DIC | None | | 22 days |
[29] | 46 | F | 115 | 59 | No | DIC | None | | 8 days |
[30] | 43 | M | 53 | NR | No | HUS | None | | Surgery, no recurrence |
[31] | 66 | M | 70 | 250 | No | MAHA | 5-FU 425 mg/m2 and leucovorin 20 mg/m2 daily | 5-FU 425 mg/m2 and leucovorin 20 mg/m2 daily | 26 months |
[32] | NR | NR | 43 | 45 | No | MAHA | Cisplatin/5-FU | | 2 days |
[33] | 50 | M | 85 | 95 | No | Pulmonary tumour Thrombotic microangiopathy | 5-FU 250 mg daily, mitomycin C 7 mg weekly, and cisplatin 125 mg once | | 86 days |
[34] | 66 | M | 73 | 28 | No | Hemol. anemia | None | | 15 days |
[34] | 43 | M | 91 | 50 | | Hemol. anemia | None | | 7 days |
[35] | 43 | M | 78 | 62 | No | DIC/MAHA | MMC, 5-FU, Ara-C, and heparin | | 6 months |
[36] | 27 | F | 72 | 23 | Yes | Thrombotic microangiopathy | None | | 3 days |
Our case | 49 | M | 52 | 76 | Yes | CR-MAHA | Cisplatin 50 mg/m2 day 1, 5-FU infusion 1000 mg/m2/day, days 1 through 4, all every 21 days | Docetaxel 25 mg/m2 weekly, cisplatin 60 mg/m2 every 21 days, and 200 mg/m2 5-FU infusion daily | 16 months |
|